DE69434258D1 - Mikroverkapselte 1,2-benzazole - Google Patents

Mikroverkapselte 1,2-benzazole

Info

Publication number
DE69434258D1
DE69434258D1 DE69434258T DE69434258T DE69434258D1 DE 69434258 D1 DE69434258 D1 DE 69434258D1 DE 69434258 T DE69434258 T DE 69434258T DE 69434258 T DE69434258 T DE 69434258T DE 69434258 D1 DE69434258 D1 DE 69434258D1
Authority
DE
Germany
Prior art keywords
benzazole
capsulated
micro
risperidone
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434258T
Other languages
English (en)
Other versions
DE69434258T2 (de
Inventor
Jean Louis Mesens
Michael E Rickey
Thomas J Atkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Alkermes Inc
Original Assignee
Janssen Pharmaceutica NV
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22551225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69434258(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV, Alkermes Inc filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE69434258D1 publication Critical patent/DE69434258D1/de
Publication of DE69434258T2 publication Critical patent/DE69434258T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69434258T 1993-11-19 1994-11-11 Mikroverkapselte 1,2-benzazole Expired - Lifetime DE69434258T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US154403 1988-02-10
US15440393A 1993-11-19 1993-11-19
PCT/EP1994/003754 WO1995013814A1 (en) 1993-11-19 1994-11-11 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

Publications (2)

Publication Number Publication Date
DE69434258D1 true DE69434258D1 (de) 2005-03-10
DE69434258T2 DE69434258T2 (de) 2006-01-19

Family

ID=22551225

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434258T Expired - Lifetime DE69434258T2 (de) 1993-11-19 1994-11-11 Mikroverkapselte 1,2-benzazole

Country Status (30)

Country Link
US (11) US5688801A (de)
EP (1) EP0729357B1 (de)
JP (1) JP3645906B2 (de)
KR (1) KR100354270B1 (de)
CN (1) CN1074923C (de)
AT (1) ATE288270T1 (de)
AU (1) AU694147B2 (de)
BG (1) BG63246B1 (de)
CL (1) CL2004001182A1 (de)
CZ (1) CZ293764B6 (de)
DE (1) DE69434258T2 (de)
DK (1) DK0729357T3 (de)
ES (1) ES2236700T3 (de)
FI (1) FI117122B (de)
HK (1) HK1010694A1 (de)
HU (1) HU219487B (de)
IL (1) IL111647A (de)
MX (1) MX9408969A (de)
MY (1) MY113298A (de)
NO (1) NO309226B1 (de)
NZ (1) NZ276088A (de)
PL (1) PL314481A1 (de)
PT (1) PT729357E (de)
RO (1) RO119224B1 (de)
RU (1) RU2178695C2 (de)
SG (1) SG47445A1 (de)
SI (1) SI0729357T1 (de)
SK (1) SK282231B6 (de)
WO (1) WO1995013814A1 (de)
ZA (1) ZA949191B (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
SG47445A1 (en) 1993-11-19 1998-04-17 Janssen Pharmaceutica Nv Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles
CA2474701C (en) * 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
JP2000507544A (ja) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 痛みの治療方法
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
ES2183172T3 (es) * 1996-05-07 2003-03-16 Alkermes Inc Procedimiento para la preparacion de microparticulas.
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
EP1019384A1 (de) * 1997-02-04 2000-07-19 Dong Wha Pharmaceutical Industrial Co. Ltd. 3-amino-1,2-benzisoxazol-derivate, verfahren zu ihrer herstellung und ihre verwendung
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6194006B1 (en) * 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
FR2797784B1 (fr) * 1999-08-27 2001-11-30 Mainelab Procede d'encapsulation de matieres actives par coacervation de polymeres en solvant organique non-chlore
KR100373485B1 (ko) * 1999-09-28 2003-02-25 한국과학기술연구원 신규한 이소옥사졸 피페라진 유도체 및 그 제조방법
US6331317B1 (en) * 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6705757B2 (en) * 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6362308B1 (en) 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
EP1355630B1 (de) * 2000-08-15 2009-11-25 The Board Of Trustees Of The University Of Illinois Verfahren zur herstellung von mikropartikeln
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US20020114843A1 (en) * 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
CN1578664A (zh) 2001-10-30 2005-02-09 诺瓦提斯公司 伊潘立酮和星状聚合物的贮库制剂
KR100789567B1 (ko) * 2001-11-06 2007-12-28 동화약품공업주식회사 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도
ES2665999T3 (es) * 2002-05-31 2018-04-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para la liberación sostenida de buprenorfina
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR20040034996A (ko) * 2002-10-18 2004-04-29 한미약품 주식회사 리스페리돈의 개선된 제조방법
DK1610791T3 (da) * 2003-03-31 2011-05-09 Titan Pharmaceuticals Inc Implanterbar polymer anordning for vedvarende frigivelse af dopamin-agonist
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
AU2004285448C1 (en) * 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
US7309500B2 (en) * 2003-12-04 2007-12-18 The Board Of Trustees Of The University Of Illinois Microparticles
AU2005206143B2 (en) * 2004-01-12 2010-12-16 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
PL1734971T3 (pl) 2004-04-15 2012-08-31 Alkermes Pharma Ireland Ltd Urządzenie o przedłużonym uwalnianiu na bazie polimeru
CA2565296C (en) * 2004-04-30 2014-06-03 Abraxis Bioscience, Inc. Sustained-release microspheres and methods of making and using same
US20050260272A1 (en) * 2004-05-05 2005-11-24 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
FR2869801B1 (fr) * 2004-05-05 2008-09-12 Ethypharm Sa Procede de preparation de compositions a liberation prolongee et utilisation de ces compositions pour le traitement des affections chroniques du systeme nerveux central (snc)
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US7748343B2 (en) 2004-11-22 2010-07-06 The Board Of Trustees Of The University Of Illinois Electrohydrodynamic spraying system
WO2006078841A1 (en) * 2005-01-21 2006-07-27 President And Fellows Of Harvard College Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1743638A1 (de) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmazeutische Formulierungen von substituierten Pyrazolinderivaten
KR101283946B1 (ko) * 2005-07-18 2013-07-15 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 약물 함유 임플란트 및 그의 사용 방법
DE102005034925B4 (de) * 2005-07-26 2008-02-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Magnetorheologische Elastomerkomposite sowie deren Verwendung
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7669732B2 (en) * 2005-10-25 2010-03-02 Imi Cornelius Inc. Cup lid dispenser
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
CA2642761A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
CN102274557B (zh) 2006-08-09 2014-12-03 精达制药公司 渗透性递送系统和活塞组件
CN101511347B (zh) * 2006-08-31 2012-11-28 Sk化学株式会社 含药物微球的制造方法及由该方法制造的含药物微球
WO2008118712A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
DE102007017589B3 (de) * 2007-04-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Dämpfungsvorrichtung mit feldsteuerbarer Flüssigkeit
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
RU2485941C2 (ru) * 2007-06-25 2013-06-27 Оцука Фармасьютикал Ко., Лтд. Микросферы, имеющие структуру ядро/оболочка
CA2695178C (en) 2007-07-31 2015-06-23 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
AU2009314787B2 (en) 2008-11-14 2014-03-06 Ewha University-Industry Collaboration Foundation Method for preparing microspheres and microspheres produced thereby
US20100189800A1 (en) * 2009-01-23 2010-07-29 Peter Markland Continous double emulsion process for making microparticles
CA2775676C (en) 2009-09-28 2016-08-16 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
WO2011042450A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Carrier linked paliperidone prodrugs
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
US8641900B2 (en) * 2009-11-05 2014-02-04 Taiwan Biotech Co., Ltd Method and device for continuously preparing microspheres, and collection unit thereof
EA015780B1 (ru) * 2010-03-11 2011-12-30 Общество С Ограниченной Ответственностью "Цэм" (Ооо "Цэм") Фармацевтическая композиция пролонгированного действия для снижения аппетита
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
CA2796756A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
HRP20211853T1 (hr) 2010-05-31 2022-03-04 Laboratorios Farmaceuticos Rovi, S.A. Sastavi in situ injekcijskih biorazgradivih implantata
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
PT2394664T (pt) 2010-05-31 2016-09-06 Farm Rovi Lab Sa Composição depot para injetável antipsicótico
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
SG191414A1 (en) * 2010-12-29 2013-08-30 Medincell Biodegradable drug delivery compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP3772354B1 (de) 2011-04-25 2023-11-01 Geneora Pharma (Shijiazhuang) Co., Ltd. Zusammensetzung aus risperidon-mikrokügelchen mit verzögerter freisetzung
RS62059B1 (sr) 2011-05-31 2021-07-30 Laboratorios Farmaceuticos Rovi S A Kompozicija implanta risperidona i/ili paliperidona
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
US20150080404A1 (en) 2012-04-14 2015-03-19 Intra-Cellular Therapies, Inc. Novel compositions and methods
EP2846772A4 (de) 2012-05-10 2015-12-30 Painreform Ltd Depotformulierungen eines hydrophoben wirkstoffes und verfahren zur herstellung davon
DE102013011399A1 (de) 2012-07-31 2014-02-06 Amw Gmbh Implantat mit Risperidon
AU2013305938B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to paliperidone haptens and use thereof
CN108517014A (zh) 2012-08-21 2018-09-11 詹森药业有限公司 利培酮半抗原的抗体及其用途
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
PT2888593T (pt) 2012-08-21 2018-12-12 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilizações dos mesmos
EP2968320B1 (de) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Organische verbindungen
RU2552303C2 (ru) * 2013-07-02 2015-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ получения фармацевтической композиции, содержащей алпразолам
CN105722503A (zh) * 2013-08-06 2016-06-29 东国制药株式会社 恩替卡韦微球及包含其的非口服给药用药学组合物
WO2015036244A1 (en) * 2013-09-13 2015-03-19 Continental Automotive Gmbh Fluid injector
MX2016007219A (es) 2013-12-03 2016-09-16 Intra-Cellular Therapies Inc Metodos novedosos.
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
WO2015154030A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
ES2961843T3 (es) 2014-04-04 2024-03-14 Intra Cellular Therapies Inc Gamma-carbolinas condensadas con heterociclo deuteradas como antagonistas de los receptores de 5-HT2A
US10179776B2 (en) 2014-06-09 2019-01-15 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
TW201613564A (en) * 2014-08-06 2016-04-16 Tty Biopharm Co Ltd Process for the preparation of sustained-release microparticles having a controllable release profile
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
DK3377041T3 (da) 2015-11-16 2023-12-18 Medincell S A Fremgangsmåde til fragmentering og/eller målretning af farmaceutisk aktive bestanddele til synovialvæv
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
MX2018009158A (es) 2016-01-26 2018-11-19 Intra Cellular Therapies Inc Compuestos organicos.
DK3407889T3 (da) 2016-03-25 2021-08-09 Intra Cellular Therapies Inc Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
EP3458084B1 (de) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Für den glucagonrezeptor selektive polypeptide und verfahren zu deren verwendung
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3562484B1 (de) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalinderivate zur behandlung von erkrankungen des zns
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
IL268970B2 (en) 2017-03-24 2023-12-01 Intra Cellular Therapies Inc Oral preparations of heterocyclic gamma carboline derivatives fused for absorption through mucous membranes
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
MX2020000968A (es) 2017-07-26 2020-09-28 Intra Cellular Therapies Inc Compuestos organicos.
US11427587B2 (en) 2017-07-26 2022-08-30 Intra-Cellular Therapies, Inc. Organic compounds
RU2702012C2 (ru) * 2017-10-24 2019-10-03 федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ получения фармацевтической композиции, содержащей пентоксифиллин
WO2019183341A1 (en) 2018-03-23 2019-09-26 Intra-Cellular Therapies, Inc. Organic compounds
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
WO2020086629A1 (en) * 2018-10-22 2020-04-30 The General Hospital Corporation Complexes and ligands
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
AU2022351480A1 (en) 2021-09-21 2024-03-28 Laboratorios Farmacéuticos Rovi, S.A. Antipsychotic injectable extended-release composition
WO2023225620A1 (en) 2022-05-18 2023-11-23 Intra-Cellular Therapies, Inc. Novel methods

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634668A (de) * 1962-07-11
US3197180A (en) * 1963-10-11 1965-07-27 Chemineer Mixing device
US3415493A (en) * 1967-08-21 1968-12-10 Chemineer Mixing device
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE2010115A1 (de) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Mikrogranulaten
GB1351811A (en) * 1971-05-07 1974-05-01 Kenics Corp Mixing device
JPS523342B2 (de) * 1972-01-26 1977-01-27
GB1413186A (en) * 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4034965A (en) * 1973-12-27 1977-07-12 Komax Systems, Inc. Material distributing and mixing apparatus
US3923288A (en) * 1973-12-27 1975-12-02 Komax Systems Inc Material mixing apparatus
US4128641A (en) * 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
US4111402A (en) * 1976-10-05 1978-09-05 Chemineer, Inc. Motionless mixer
JPS54127064A (en) * 1978-03-06 1979-10-02 Komax Systems Inc Charging instrument of stationary mixer
DE2822096A1 (de) * 1978-05-20 1979-11-22 Bayer Ag Gebohrte mischelemente fuer statische und dynamische mischer
US4489055A (en) * 1978-07-19 1984-12-18 N.V. Sopar S.A. Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use
US4208136A (en) * 1978-12-01 1980-06-17 Komax Systems, Inc. Static mixing apparatus
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
US4329331A (en) * 1980-03-13 1982-05-11 Kallick Charles A Diagnostic method for detection of systemic lupus erythematosus
US4342870A (en) * 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4324870A (en) * 1980-06-23 1982-04-13 Uniroyal, Inc. Scorch-safe acceleration of urethane vulcanization of unsaturated rubbers
US4337261A (en) * 1980-07-28 1982-06-29 Hoechst-Roussel Pharmaceuticals Inc. (1,2-Benzisoxazol)phenoxyacetic acids as diuretics
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4443451A (en) * 1981-07-15 1984-04-17 Janssen Pharmaceutica N.V. Bicyclic pyrimidin-5-one derivatives
DE3274720D1 (en) * 1981-07-28 1987-01-29 Statiflo Inc Static mixers
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
US4529727A (en) * 1982-04-21 1985-07-16 Janssen Pharmaceutical, N.V. Pyrimido[2,1-b][1,3]-thiazines
US4798786A (en) * 1982-05-06 1989-01-17 Stolle Research And Development Corporation Living cells encapsulated in crosslinked protein
GB2120113B (en) * 1982-05-13 1985-10-09 Komax Systems Inc Mixing in flow
US4808007A (en) * 1982-05-13 1989-02-28 Komax Systems, Inc. Dual viscosity mixer
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4542025A (en) * 1982-07-29 1985-09-17 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4485107A (en) * 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
US4511258A (en) * 1983-03-25 1985-04-16 Koflo Corporation Static material mixing apparatus
US4458076A (en) * 1983-05-31 1984-07-03 Hoechst-Roussel Pharmaceuticals 3-(4-Piperidinyl)-1,2-benzisothiazoles
ATE34407T1 (de) * 1983-06-22 1988-06-15 Stolle Res & Dev Eingekapselte zellen, verfahren zu deren herstellung und ihre verwendung.
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
US4696258A (en) * 1984-04-04 1987-09-29 The Magrath Company Method and substance for the detection of cows in estrus
US4585482A (en) * 1984-05-25 1986-04-29 Southern Research Institute Long-acting biocidal compositions and method therefor
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4665075A (en) * 1984-12-05 1987-05-12 Janssen Pharmaceutica N.V. Derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines
US4614440A (en) * 1985-03-21 1986-09-30 Komax Systems, Inc. Stacked motionless mixer
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US4689330A (en) * 1985-04-15 1987-08-25 Janssen Pharmaceutica N.V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
US4616937A (en) * 1985-04-16 1986-10-14 Komax Systems, Inc. Intermittent mixing apparatus
HUT43600A (en) * 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
US4643584A (en) * 1985-09-11 1987-02-17 Koch Engineering Company, Inc. Motionless mixer
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
EP0248531A3 (de) * 1986-05-02 1988-09-28 Southern Research Institute Verkapselte Nukleinsäuren
WO1988001165A1 (en) * 1986-08-11 1988-02-25 Innovata Biomed Limited Pharmaceutical formulations comprising microcapsules
US4765204A (en) * 1986-09-03 1988-08-23 Koch Engineering Company, Inc. Method of manufacturing a motionless mixer
US4731205A (en) * 1986-09-08 1988-03-15 Koch Engineering Company, Inc. Random packing for fluid contact devices and method of preparing said packing
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US4753535A (en) * 1987-03-16 1988-06-28 Komax Systems, Inc. Motionless mixer
US4793713A (en) * 1987-04-06 1988-12-27 Komax Systems, Inc. Rotary mixer
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5143661A (en) 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
EP0349486A3 (de) * 1988-06-29 1990-12-05 Ciba-Geigy Ag Azofarbstoffe, deren Herstellung und Verwendung
US4936689A (en) * 1988-07-11 1990-06-26 Koflo Corporation Static material mixing apparatus
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2050911C (en) * 1989-05-04 1997-07-15 Thomas R. Tice Encapsulation process and products therefrom
HU221294B1 (en) 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
ATE135216T1 (de) 1989-08-21 1996-03-15 Beth Israel Hospital Verwendung von spiperone-derivate zur immunosuppression
US5478564A (en) * 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
AU7558991A (en) * 1990-03-15 1991-10-10 United States Of America, As Represented By The Secretary Of The Army, The Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
CA2040141C (en) 1990-04-13 2002-05-14 Minoru Yamada Biodegradable high-molecular polymers, production and use therof
WO1991017772A1 (en) * 1990-05-16 1991-11-28 Southern Research Institute Controlled release dopamine and its use to stimulate nerve fiber growth
MY108621A (en) * 1990-08-01 1996-10-31 Novartis Ag Polylactide preparation and purification
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
JP3180421B2 (ja) * 1992-03-30 2001-06-25 日本電気株式会社 テスト回路を内蔵したアナログ・ディジタル混在マスタ
DE4223169C1 (de) 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
DE69327542T2 (de) * 1992-11-17 2000-07-06 Yoshitomi Pharmaceutical Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
DE4244466C2 (de) 1992-12-24 1995-02-23 Pharmatech Gmbh Verfahren zur Herstellung von Pseudolatices und Mikro- oder Nanopartikeln und deren Verwendung zur Herstellung von pharmazeutischen Präparaten
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DK0724433T3 (da) 1993-10-22 1999-08-30 Genentech Inc Fremgangsmåde til fremstilling af mikrosfærer med et tørringstrin i fluidiseret leje
US6080429A (en) 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
CA2474701C (en) * 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
SG47445A1 (en) * 1993-11-19 1998-04-17 Janssen Pharmaceutica Nv Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles
PT754032E (pt) 1994-04-08 2002-05-31 Atrix Lab Inc Composicoes liquidas para difusao
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
ES2205481T3 (es) 1997-04-17 2004-05-01 Amgen Inc. Microparticulas biodegradables para la liberacion sostenida de farmacos terapeuticos.
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
SE9903236D0 (sv) 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
DE10055742B4 (de) 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen

Also Published As

Publication number Publication date
MY113298A (en) 2002-01-31
NO962040D0 (no) 1996-05-20
US6368632B1 (en) 2002-04-09
PL314481A1 (en) 1996-09-16
HUT73501A (en) 1996-08-28
EP0729357A1 (de) 1996-09-04
HK1010694A1 (en) 1999-06-25
FI117122B (fi) 2006-06-30
RU2178695C2 (ru) 2002-01-27
US5688801A (en) 1997-11-18
MX9408969A (es) 1997-03-29
US5965168A (en) 1999-10-12
CZ137396A3 (en) 1996-08-14
US6803055B2 (en) 2004-10-12
IL111647A (en) 1999-12-22
SK282231B6 (sk) 2001-12-03
FI962111A0 (fi) 1996-05-17
ATE288270T1 (de) 2005-02-15
SG47445A1 (en) 1998-04-17
US5770231A (en) 1998-06-23
NZ276088A (en) 1999-07-29
IL111647A0 (en) 1995-01-24
HU219487B (hu) 2001-04-28
KR100354270B1 (ko) 2003-02-11
CN1074923C (zh) 2001-11-21
JP3645906B2 (ja) 2005-05-11
DK0729357T3 (da) 2005-06-06
CL2004001182A1 (es) 2005-06-03
SK64096A3 (en) 1997-06-04
CZ293764B6 (cs) 2004-07-14
US20050025828A1 (en) 2005-02-03
BG63246B1 (bg) 2001-07-31
NO962040L (no) 1996-07-15
ES2236700T3 (es) 2005-07-16
US7547452B2 (en) 2009-06-16
US20080063721A1 (en) 2008-03-13
US6110921A (en) 2000-08-29
US20020098233A1 (en) 2002-07-25
FI962111A (fi) 1996-05-17
WO1995013814A1 (en) 1995-05-26
HU9501942D0 (en) 1995-09-28
RO119224B1 (ro) 2004-06-30
EP0729357B1 (de) 2005-02-02
ZA949191B (en) 1996-05-20
SI0729357T1 (en) 2005-06-30
JPH09505286A (ja) 1997-05-27
NO309226B1 (no) 2001-01-02
PT729357E (pt) 2005-06-30
DE69434258T2 (de) 2006-01-19
BG100632A (bg) 1997-03-31
US20080069885A1 (en) 2008-03-20
US7118763B2 (en) 2006-10-10
US20060182810A1 (en) 2006-08-17
AU8142594A (en) 1995-06-06
US6544559B2 (en) 2003-04-08
US20030165571A1 (en) 2003-09-04
CN1137756A (zh) 1996-12-11
AU694147B2 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
DE69434258D1 (de) Mikroverkapselte 1,2-benzazole
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ES2173096T3 (es) Composicion farmaceutica peletizada.
NO20065995L (no) Mikropartikler
DE3581819D1 (de) Pyridazinamine wirksam gegen viren.
ATE272394T1 (de) Zubereitung mit verzögerter freisetzung
TR200103178T2 (tr) İntegrinlerin reseptörlere bağlanmasını engelleyen karboksilik asit türevleri.
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
DK1024795T3 (da) Formuleringer med reguleret frigivelse
DE60014369D1 (de) Propansäurederivate, die die bindung von integrinen an ihre rezeptoren behindern
PT885014E (pt) Composicoes farmaceuticas contendo polimeros orto ester tamponados
IT1247945B (it) Agente avente attivita' batteriostatica e battericida
RS50046B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
HK1043945A1 (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition